BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Engin A, Gonul II, Engin AB, Karamercan A, Sepici Dincel A, Dursun A. Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma. World J Gastroenterol 2016; 22(13): 3592-3601 [PMID: 27053851 DOI: 10.3748/wjg.v22.i13.3592]
URL: https://www.wjgnet.com/1007-9327/full/v22/i13/3592.htm
Number Citing Articles
1
Daniel J. Lin, James C. K. Ng, Lei Huang, Max Robinson, James O’Hara, Janet A. Wilson, Andrew L. Mellor. The immunotherapeutic role of indoleamine 2,3‐dioxygenase in head and neck squamous cell carcinoma: A systematic reviewClinical Otolaryngology 2021; 46(5): 919 doi: 10.1111/coa.13794
2
Lizbeth Perez‐Castro, Roy Garcia, Niranjan Venkateswaran, Spencer Barnes, Maralice Conacci‐Sorrell. Tryptophan and its metabolites in normal physiology and cancer etiologyThe FEBS Journal 2023; 290(1): 7 doi: 10.1111/febs.16245
3
Bohuslav Melichar, Klára Hrůzová, Lenka Kujovská Krčmová, Lenka Javorská, Eliška Pešková, Dagmar Solichová, Radomír Hyšpler, Eva Malířová, Milan Vošmik, Marie Bartoušková, Dušan Klos, Hana Študentová. Association of peripheral blood cell count-derived ratios, biomarkers of inflammatory response and tumor growth with outcome in previously treated metastatic colorectal carcinoma patients receiving cetuximabPteridines 2017; 28(3-4): 221 doi: 10.1515/pterid-2017-0016
4
Lukas Lanser, Patricia Kink, Eva Maria Egger, Wolfgang Willenbacher, Dietmar Fuchs, Guenter Weiss, Katharina Kurz. Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in CancerFrontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.00249
5
Ayse Basak Engin, Riza Onder Gunaydin, Sacit Altug Kesikli, Dietmar Fuchs, Ali Sefik Hosal. Serum neopterin concentrations and tryptophan degradation pattern in patients with late stage larynx carcinomaPteridines 2017; 28(2): 91 doi: 10.1515/pterid-2017-0004
6
Annabel Meireson, Inès Chevolet, Eva Hulstaert, Liesbeth Ferdinande, Piet Ost, Karen Geboes, Marc De Man, Dirk Van de Putte, Laurine Verset, Vibeke Kruse, Pieter Demetter, Lieve Brochez. Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profileOncotarget 2018; 9(38): 25216 doi: 10.18632/oncotarget.25393
7
Moein Ala. The footprint of kynurenine pathway in every cancer: a new target for chemotherapyEuropean Journal of Pharmacology 2021; 896: 173921 doi: 10.1016/j.ejphar.2021.173921
8
Ana Sebio, Breelyn A Wilky, Vicki L Keedy, Robin L Jones. The current landscape of early drug development for patients with sarcoma in the immunotherapy eraFuture Oncology 2018; 14(12): 1197 doi: 10.2217/fon-2017-0565
9
Lieve Brochez, Ines Chevolet, Vibeke Kruse. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapyEuropean Journal of Cancer 2017; 76: 167 doi: 10.1016/j.ejca.2017.01.011
10
Asami Hagiwara, Yoshiyasu Nakamura, Rumi Nishimoto, Satoko Ueno, Yohei Miyagi. Induction of tryptophan hydroxylase in the liver of s.c. tumor model of prostate cancerCancer Science 2020; 111(4): 1218 doi: 10.1111/cas.14333
11
Jinhao Liu, Jikun Wang, Xueqian Ma, Yang Feng, Yanlei Chen, Yanping Wang, Dong Xue, Shifeng Qiao. <p>Study of the Relationship Between Serum Amino Acid Metabolism and Lymph Node Metastasis in Patients with Colorectal Cancer</p>OncoTargets and Therapy 2020; : 10287 doi: 10.2147/OTT.S273107
12
Ayse Basak Engin, Atilla Engin. Protein Kinase-mediated Decisions Between Life and DeathAdvances in Experimental Medicine and Biology 2021; 1275: 339 doi: 10.1007/978-3-030-49844-3_13
13
Eva Ott, Linda Bilonda, Delphine Dansette, Cécile Deleine, Emilie Duchalais, Juliette Podevin, Christelle Volteau, Jaafar Bennouna, Yann Touchefeu, Pierre Fourquier, Wassila El Alami Thomas, Jérome Chetritt, Stéphane Bezieau, Marc Denis, Claire Toquet, Jean-François Mosnier, Anne Jarry, Céline Bossard. The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite statusOncoImmunology 2019; 8(4): e1562834 doi: 10.1080/2162402X.2018.1562834
14
Diwakar Davar, Nathan Bahary. Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical ExperiencesTargeted Oncology 2018; 13(2): 125 doi: 10.1007/s11523-017-0547-9
15
Annabel Meireson, Michael Devos, Lieve Brochez. IDO Expression in Cancer: Different Compartment, Different Functionality?Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.531491